[²¹¹At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

Click to increase image sizeClick to decrease image size Disclosure statementAll authors declare no competing conflict of interest.Data availability statementFor original data and reagents, please contact the corresponding author (rwalter@fredhutch.org).Additional informationFundingResearch reported in this publication was supported by the National Institutes of Health/National Cancer Institute (NIH/NCI; R01-CA172582).